Item 5. Market for Registrant’s Common Equity
ITEM
5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market
Information
Our
stock currently is listed on the Nasdaq under the symbol “MYSZ”. Our stock has been traded on the Nasdaq since July 25, 2016.
On
December 27, 2023 our shareholders approved a voluntary delisting of our common stock from trading on the TASE. On January 11, 2024,
the TASE issued a notice confirming our request to delist our common stock from the TASE with the last day of trading on March 27, 2024.
All of the shares of our common stock on the TASE transferred to Nasdaq.
Holders
As
of April 14, 2026, we had 141 shareholders of record. The actual number of stockholders is greater than this number
of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other
nominees.
Dividend
Policy
We
have never declared or paid cash dividends on our common stock. We intend to retain our future earnings, if any, in order to reinvest
in the development and growth of our business and, therefore, do not intend to pay dividends on our common stock for the foreseeable
future. Any future determination to pay dividends will be at the discretion of our Board of Directors and will depend on our financial
condition, results of operations, capital requirements, and such other factors as our Board of Directors deems relevant.
Securities
Authorized for Issuance under Equity Compensation Plans
Information
about our equity compensation plans is incorporated herein by reference to “Item 12. Security Ownership of Certain Beneficial Owners
and Management and Related Stockholder Matters”, of this Annual Report on Form 10-K.
Recent
Sales of Unregistered Securities
In
December 2025, we issued warrants to consultants and a service provider in consideration for services rendered. The warrant issued to
the service provider is exercisable for 100,000 shares of our common stock, fully vested upon grant, with exercise prices of (i) $1.50
per share for 25,000 shares, (ii) $2.00 per share for 25,000 shares, (iii) $2.50 per share for 25,000 shares and (iv) $3.00 per share
for 25,000 shares, and has a term of 60 months from the date of issuance. The warrants issued to consultants are exercisable for an aggregate
of 70,000 shares of our common stock at an exercise price of $0.01 per share, vesting on March 1, 2026 subject to continued engagement
as consultants on such date, and have a term of 60 months from the date of issuance.
Purchasers
of Equity Securities by the Issuer and Affiliates Purchasers
We
did not repurchase any of our equity securities during the quarter ended December 31, 2025.
ITEM
6. [RESERVED]
41
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the is authoritative for anything you rely on.